Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced positive top-line results of its Phase 3 study (B2411367) in Japan evaluating the safety and efficacy of EFFEXOR® (venlafaxine ...
Viatris: EFFEXOR Meets Primary And All Secondary Efficacy Endpoints In Japan - Quick Facts
Viatris (VTRS) reported positive top-line results of Phase 3 study in Japan evaluating the safety and efficacy of EFFEXOR in adults ...
CSR Wire13h
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2024.
bovnews7h
Jefferies Issues Buy Rating for Viatris Inc (VTRS) Stock
On Tuesday, Viatris Inc (VTRS) stock saw a decline, ending the day at $11.32 which represents a decrease of $-0.01 or -0.09% from the prior close of $11.33. The stock opened at $11.33 and touched a ...
Viatris Inc (VTRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations
Viatris Inc (VTRS) reports a solid quarter with $3.8 billion in revenue and increased new product revenue expectations, despite challenges from global price regulations.
Future Market Insights14h
Injectable Drug Market Projected to Reach USD 991.63 Billion by 2034 at a 5.8% of CAGR
Injectable Drug Market. The global injectable drug market is poised for significant growth, with an estimated valuation of ...